Shionogi & Co., Ltd. (TYO:4507)
2,780.00
-53.00 (-1.87%)
Jun 19, 2026, 3:30 PM JST
Shionogi & Revenue
In the fiscal year ending March 31, 2026, Shionogi & had annual revenue of 499.68B JPY with 14.01% growth. Shionogi & had revenue of 138.99B in the quarter ending March 31, 2026, with 32.79% growth.
Revenue
499.68B
Revenue Growth
+14.01%
P/S Ratio
4.73
Revenue / Employee
100.84M
Employees
4,955
Market Cap
2.37T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 499.68B | 61.41B | 14.01% |
| Mar 31, 2025 | 438.27B | 3.19B | 0.73% |
| Mar 31, 2024 | 435.08B | 8.40B | 1.97% |
| Mar 31, 2023 | 426.68B | 91.55B | 27.32% |
| Mar 31, 2022 | 335.14B | 37.96B | 12.77% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Takeda Pharmaceutical Company | 4.51T |
| Toho Holdings | 1.55T |
| Eisai | 825.38B |
| Sumitomo Pharma | 453.29B |
| Towa Pharmaceutical | 273.71B |
| Sawai Group Holdings | 201.68B |
| Tsumura & Co. | 192.62B |
| Nippon Shinyaku | 170.77B |
Shionogi & News
- 18 days ago - Shionogi Announces FDA Approval of XOCOVA® (ensitrelvir), the First and Only Oral Option to Help Prevent COVID-19 Following Exposure - Business Wire
- 19 days ago - US regulator approves oral drug from Japan's Shionogi to prevent COVID-19 - Reuters
- 5 weeks ago - New England Journal of Medicine Publishes Shionogi Study Demonstrating Ensitrelvir Prevents COVID-19 Following Exposure - Business Wire
- 5 weeks ago - Shionogi & Quarterly report: Q4 2026 - Filings
- 5 weeks ago - Shionogi & Slides: Q4 2026 - Filings
- 2 months ago - Shionogi Receives Contract with U.S. Government Through BARDA's Project BioShield to Enhance National Preparedness for Drug-Resistant Bacterial Threats - Business Wire
- 2 months ago - Shionogi Completes Acquisition of All Rights to RADICAVA (edaravone) - Business Wire
- 3 months ago - Shionogi Announces First Patients Enrolled in Global Phase 2 Clinical Trial in Adults with Late-Onset Pompe Disease - Business Wire